Clinical trial · Interventional
Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer Patients
Transcutaneous Electrical Acupoint Stimulation Ameliorates Chemotherapy-Induced Bone Marrow Suppression in Lung Cancer Patients
NCT02663492CI-TRIAL-00020675unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the effect of percutaneous electrical stimulation on chemotherapy-induced bone marrow suppression in patients with lung cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sanguisorba officinalis L. | Drug | — | UNRESOLVED |
| TEAS | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- TEAS group
- description
- Patients with transcutaneous electrical acupoint stimulation (TEAS) group receive electrical stimulation of acupoints including Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4).
- interventionNames
- Device: TEAS
- type
- ACTIVE_COMPARATOR
- label
- Medication group
- description
- On the basis of routine nursing care, patients need to take Sanguisorba officinalis L., named Diyu Shengbai Pian (a Traditional Chinese Medicine) 3 times per day.
- interventionNames
- Drug: Sanguisorba officinalis L.
- type
- NO_INTERVENTION
- label
- Control group
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of Non-small cell lung cancer(NSCLC) * age between 20 and 75 years * chemotherapy naive after diagnosis * GP regimen as treatment * an expected survival of more than 12 weeks based on a score equal to or greater than 60 points on Karnofsky performance status (KPS) scale * the ability to understand and speak Mandarin Exclusion Criteria: * diagnosis of a hematological system tumor * mental illness * bone marrow suppression prior to chemotherapy * pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.